OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Britain Courts Anthropic Amid US Defense Department Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
BEDMINSTER, N.J., and DUBLIN, Ireland, Sept. 07, 2016 -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Rodman & Renshaw 18th Annual Global Investment Conference in New York City on Tuesday, September 13, 2016, at 3:50 p.m. ET.
A live audio webcast of the presentation will be available at:
http://wsw.com/webcast/rrshq26/amrn
About Amarin
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes a commitment to an ongoing outcomes study. Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is a highly-pure, EPA-only, omega-3 fatty acid product available by prescription. For more information about Vascepa, visit www.vascepa.com. For more information about Amarin, visit www.amarincorp.com.
Availability of Other Information about Amarin
Investors and others should note that we communicate with our investors and the public using our company website (www.amarincorp.com), our investor relations website (http://www.amarincorp.com/investor-splash.html), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in Amarin to review the information that we post on these channels, including our investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin contact information Investor Relations: Kathryn McNeil Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) 719-1315 [email protected] Lee M. Stern Trout Group In U.S.: +1 (646) 378-2922 [email protected] Media Inquiries: Ovidio Torres Finn Partners In U.S.: +1 (312) 329 3911 [email protected]
